Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
granulysin CRISPR Activation Plasmid (h): sc-403208-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- granulysin CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- granulysin CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by granulysin CRISPR Activation Plasmid (h) and granulysin CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the GNLY transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: granulysin Antibody (F-9): sc-271119
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
granulysin CRISPR Activation Plasmid (h) | sc-403208-ACT | 20 µg | $397.00 |
Human GNLY encodes granulysin, a cytolytic and proinflammatory effector protein stored in cytotoxic granules of NK cells and activated CD8+ T cells. Upon immune synapse formation, granulysin is released to promote antimicrobial activity and contribute to target-cell killing in concert with perforin and granzymes, shaping innate and adaptive immune responses. GNLY expression is linked to lymphocyte activation programs and cytotoxic differentiation states, and its dysregulation is studied in contexts of immune dysfunction, chronic infection, tumor immune surveillance, and inflammatory disease mechanisms. As a readout of cytotoxic lymphocyte biology, GNLY is frequently leveraged as a marker and functional mediator in immunology and host–pathogen interaction research.
granulysin CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GNLY expression without altering the underlying DNA sequence.
granulysin CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GNLY locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GNLY transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous granulysin expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GNLY locus and enabling the study of granulysin-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of granulysin pathway restoration in tumor cells with silenced or reduced GNLY expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.